Ryan Watts, CEO and co-founder of Denali Therapeutics, discusses his company’s mission, the progress it has made in the battle against neurodegenerative diseases, and how his personal experience of losing his mother to Alzheimer’s has underscored the urgency to develop cutting-edge therapies in this field.
Kate Ryder, founder and CEO of Maven Clinic, discusses her experience launching a startup, her efforts to eliminate gender inequity in the healthcare system, and her perspective on the future of telemedicine.
In this episode of Exchanges at Goldman Sachs, Salveen Richter, Lead Analyst for the U.S. Biotechnology Sector in Goldman Sachs Research, explains how new innovations in gene editing are transforming the future of medicine and the greater biotech investment landscape.
Dr. Scott Gottlieb, Author of Uncontrolled Spread; Former FDA Commissioner; Board Member, Pfizer and Illumina
Dr. Scott Gottlieb, former FDA commissioner, Pfizer and Illumina board member, and author of Uncontrolled Spread, discusses the threat of the Omicron variant, lessons learned from the collective response to the pandemic, and prescriptions for how the country can better prepare for the next outbreak.
How has the healthcare sector fared during the pandemic? We spoke with Jenny Chang, a portfolio manager who covers healthcare for Goldman Sachs Asset Management’s Fundamental Equity team, on the sectors she and her team are focused on this year.
The hospitals and healthcare systems that are critical to managing our health are also a significant part of the institutional investor landscape. We sat down with Paget MacColl, co-head of the Americas Institutional Client Business within Goldman Sachs Asset Management (GSAM), to discuss the results of GSAM’s 2020 Healthcare Diagnostic, an annual survey assessing the investment approaches and practices of 42 leading healthcare systems and hospitals across the U.S. representing more than $350 billion in investments.
Salveen Richter, lead analyst for the US Biotechnology sector in Goldman Sachs Research, talks about Pfizer’s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.
Jenny Chang, portfolio manager for Goldman Sachs Asset Management’s Fundamental Equity team, discusses how the pandemic is driving innovation and increased collaboration across the healthcare industry.
What if there was a way to make clinical trials faster, cheaper and more successful? Robert P. Jones of Goldman Sachs Research explains how broader adoption of technologies like artificial intelligence and cloud computing could transform clinical trials and drive a significant reduction in drug development costs. Watch Video
Amid many concerns heading into 2020, the event that no one expected was the outbreak of COVID-19—a coronavirus that first emerged in the populous city of Wuhan, China, and which is now proving to be both more infectious and virulent than the common flu. As China attempts to restart its economy after an unprecedented lockdown, the virus continues to spread globally, and data on the sizeable economic fallout starts to trickle in, coronavirus is Top of Mind.
The hospitals and healthcare systems that are critical to managing our health are also, with more than $1 trillion in investments, a significant part of the institutional investor landscape. We sat down with Paget MacColl of Goldman Sachs Asset Management (GSAM), which recently released the results of its Healthcare Diagnostic, an annual survey assessing the investment approaches and practices of the nation’s largest nonprofit healthcare systems and hospitals. In our interview, Paget discussed the role of investments amid an increasingly challenging operating environment.
2019 is set to be a record year for healthcare technology. Goldman Sachs Investment Banking Division explains the rise in activity in this episode of The Long & Short of It. Watch Video
Marshall Smith, global head of healthcare investment banking at Goldman Sachs, discusses how healthcare corporations are driving growth amid macro and industry-specific uncertainty. Listen Now